Indaptus Therapeutics (INDP) News Today $1.00 -0.04 (-3.85%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private PlacementNovember 22 at 8:36 AM | globenewswire.comMaxim Group Lowers Indaptus Therapeutics (NASDAQ:INDP) Price Target to $5.00November 17, 2024 | americanbankingnews.comIndaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | markets.businessinsider.comIndaptus Therapeutics price target lowered to $5 from $8 at MaximNovember 13, 2024 | markets.businessinsider.comIndaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in ImmunologyNovember 11, 2024 | globenewswire.comIndaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual MeetingNovember 7, 2024 | globenewswire.comIndaptus Therapeutics to Present at Two Upcoming Investor ConferencesOctober 23, 2024 | globenewswire.comIndaptus Therapeutics Shares Rise After Pact to Develop Cancer TreatmentOctober 22, 2024 | marketwatch.comIndaptus Therapeutics announces clinical supply agreement with BeiGeneOctober 22, 2024 | markets.businessinsider.comIndaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer ImmunotherapyOctober 10, 2024 | markets.businessinsider.comIndaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitOctober 8, 2024 | finance.yahoo.comIndaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | finance.yahoo.comIndaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 12, 2024 | markets.businessinsider.comInsider Buyers Lose US$41k As Indaptus Therapeutics Sheds US$1.2mAugust 11, 2024 | finance.yahoo.comIndaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private PlacementAugust 8, 2024 | markets.businessinsider.comIndaptus stock dips on $3M securities offeringAugust 8, 2024 | msn.comIndaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual MeetingMay 29, 2024 | finance.yahoo.comIndaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid TumorsMay 22, 2024 | finance.yahoo.comINDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024May 8, 2024 | investorplace.comIndaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.comBuy Rating Affirmed for Indaptus Therapeutics Amidst Promising Clinical Advances and Potential Market ImpactApril 16, 2024 | markets.businessinsider.comIndaptus reveals immune-boosting cancer therapy dataApril 12, 2024 | investing.comBuy Rating for Indaptus Therapeutics: Promising Oncology Breakthrough with Decoy20 PlatformApril 12, 2024 | markets.businessinsider.comIndaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual MeetingApril 11, 2024 | globenewswire.comArmaguard rebuffs $26m cash lifelineMarch 28, 2024 | msn.comIndaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 28, 2024 | finance.yahoo.comIndaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual MeetingMarch 25, 2024 | globenewswire.comIndaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024March 18, 2024 | finance.yahoo.comIndaptus Dives on Quarterly ResultsMarch 13, 2024 | msn.comIndaptus Therapeutics: Q4 Earnings InsightsMarch 13, 2024 | benzinga.comIndaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateMarch 13, 2024 | globenewswire.comIndaptus Reports Positive Decoy20 Results, To Advance To Multi-dosing; Stock Up In Pre-marketMarch 4, 2024 | markets.businessinsider.comIndaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortMarch 4, 2024 | globenewswire.comIndaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortMarch 4, 2024 | globenewswire.comIndaptus Therapeutics Stock (NASDAQ:INDP) Insider TradesFebruary 25, 2024 | benzinga.comIndaptus Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceFebruary 15, 2024 | finance.yahoo.comIndaptus Therapeutics Expands Digital Presence with Launch of Social Media ChannelsFebruary 8, 2024 | finance.yahoo.comEuropean Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform TechnologyJanuary 4, 2024 | finance.yahoo.comIndaptus Therapeutics, Inc. (INDP) stock forecast and price targetDecember 22, 2023 | finance.yahoo.comIndaptus Therapeutics (INDP) Price Target Increased by 25.00% to 10.20November 27, 2023 | msn.comAnalysts Conflicted on These Healthcare Names: Ventyx Biosciences (VTYX) and Indaptus Therapeutics (INDP)November 7, 2023 | markets.businessinsider.comIndaptus Therapeutics GAAP EPS of -$0.47 beats by $0.05November 6, 2023 | msn.comIndaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 6, 2023 | finance.yahoo.comIndaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 StudyNovember 6, 2023 | finance.yahoo.comIndaptus Therapeutics: Promising Phase 1 Results and Optimistic Valuation Bolster Buy RatingNovember 4, 2023 | markets.businessinsider.comIndaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy MeetingOctober 31, 2023 | finance.yahoo.comHere's Why We're Watching Indaptus Therapeutics' (NASDAQ:INDP) Cash Burn SituationOctober 9, 2023 | finance.yahoo.comIndaptus Therapeutics to Present at the LD Micro Main Event XVISeptember 27, 2023 | finance.yahoo.comRegistration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023September 26, 2023 | finance.yahoo.comIndaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20September 19, 2023 | finance.yahoo.com Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention. Get your FREE, no-obligation Wealth Protection Guide now INDP Media Mentions By Week INDP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INDP News Sentiment▼-0.170.49▲Average Medical News Sentiment INDP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INDP Articles This Week▼20▲INDP Articles Average Week Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AFMD News RVPH News RLYB News OSTX News BRNS News ANEB News CVM News LUMO News CERO News OKYO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INDP) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
